
    
      HBeAg negative patients with HBV DNA load â‰¥1000copies/ml after 3 months of peginterferon
      alpha 2a treatment would be randomize enrolled into two groups, in Interventional group,
      patients will receive entecavir combine with peginterferon alpha 2a treatment for 48 weeks
      and followed 24 weeks. Patients in control group will be continue treated only by
      peginterferon alpha 2a for 48 weeks and followed 24 weeks after treatment. Serum HBV DNA
      load, HBsAg/anti-HBs level, HBeAg/anti-HBe will be tested at enrollment and every 3 months
      during the treatment course. Parameters of Liver and kidney function, and liver ultrasound
      examination will be tested with intervals 1-3 months. The efficacies of combined therapy were
      evaluated by the rate of sustained viral response after 48 weeks treatment and 24 weeks
      follow up compared with control group.
    
  